Kamunkhwala Gausi1, Elisa H Ignatius2, Xin Sun3, Soyeon Kim4, Laura Moran5, Lubbe Wiesner1, Florian von Groote-Bidlingmaier6, Richard Hafner7, Kathleen Donahue8, Naadira Vanker6, Susan L Rosenkranz3, Susan Swindells9, Andreas H Diacon6, Eric L Nuermberger2, Kelly E Dooley2, Paolo Denti1. 1. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. 2. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 4. Frontier Science Foundation, Brookline Massachusetts. 5. Social and Scientific Systems, a DLH Company, Silver Spring, Maryland. 6. TASK Applied Science and Stellenbosch University, Cape Town, South Africa. 7. Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland. 8. Frontier Science Foundation, Amherst, New York; and. 9. Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Abstract
Rationale: There is accumulating evidence that higher-than-standard doses of isoniazid are effective against low-to-intermediate-level isoniazid-resistant strains of Mycobacterium tuberculosis, but the optimal dose remains unknown. Objectives: To characterize the association between isoniazid pharmacokinetics (standard or high dose) and early bactericidal activity against M. tuberculosis (drug sensitive and inhA mutated) and N-acetyltransferase 2 status. Methods: ACTG (AIDS Clinical Trial Group) A5312/INHindsight is a 7-day early bactericidal activity study with isoniazid at a normal dose (5 mg/kg) for patients with drug-sensitive bacteria and 5, 10, and 15 mg/kg doses for patients with inhA mutants. Participants with pulmonary tuberculosis received daily isoniazid monotherapy and collected sputum daily. Colony-forming units (cfu) on solid culture and time to positivity in liquid culture were jointly analyzed using nonlinear mixed-effects modeling. Measurements and Main Results: Fifty-nine adults were included in this analysis. A decline in sputum cfu was described by a one-compartment model, whereas an exponential bacterial growth model was used to interpret time-to-positivity data. The model found that bacterial kill is modulated by isoniazid concentration using an effect compartment and a sigmoidal Emax relationship (a model linking the drug concentration to the observed effect). The model predicted lower potency but similar maximum kill of isoniazid against inhA-mutated compared with drug-sensitive isolates. Based on simulations from the pharmacokinetics-pharmacodynamics model, to achieve a drop in bacterial load comparable to 5 mg/kg against drug-sensitive tuberculosis, 10- and 15-mg/kg doses are necessary against inhA-mutated isolates in slow and intermediate N-acetyltransferase 2 acetylators, respectively. Fast acetylators underperformed even at 15 mg/kg. Conclusions: Dosing of isoniazid based on N-acetyltransferase 2 acetylator status may help patients attain effective exposures against inhA-mutated isolates. Clinical trial registered with www.clinicaltrials.gov (NCT01936831).
Rationale: There is accumulating evidence that higher-than-standard doses of isoniazid are effective against low-to-intermediate-level isoniazid-resistant strains of Mycobacterium tuberculosis, but the optimal dose remains unknown. Objectives: To characterize the association between isoniazid pharmacokinetics (standard or high dose) and early bactericidal activity against M. tuberculosis (drug sensitive and inhA mutated) and N-acetyltransferase 2 status. Methods: ACTG (AIDS Clinical Trial Group) A5312/INHindsight is a 7-day early bactericidal activity study with isoniazid at a normal dose (5 mg/kg) for patients with drug-sensitive bacteria and 5, 10, and 15 mg/kg doses for patients with inhA mutants. Participants with pulmonary tuberculosis received daily isoniazid monotherapy and collected sputum daily. Colony-forming units (cfu) on solid culture and time to positivity in liquid culture were jointly analyzed using nonlinear mixed-effects modeling. Measurements and Main Results: Fifty-nine adults were included in this analysis. A decline in sputum cfu was described by a one-compartment model, whereas an exponential bacterial growth model was used to interpret time-to-positivity data. The model found that bacterial kill is modulated by isoniazid concentration using an effect compartment and a sigmoidal Emax relationship (a model linking the drug concentration to the observed effect). The model predicted lower potency but similar maximum kill of isoniazid against inhA-mutated compared with drug-sensitive isolates. Based on simulations from the pharmacokinetics-pharmacodynamics model, to achieve a drop in bacterial load comparable to 5 mg/kg against drug-sensitive tuberculosis, 10- and 15-mg/kg doses are necessary against inhA-mutated isolates in slow and intermediate N-acetyltransferase 2 acetylators, respectively. Fast acetylators underperformed even at 15 mg/kg. Conclusions: Dosing of isoniazid based on N-acetyltransferase 2 acetylator status may help patients attain effective exposures against inhA-mutated isolates. Clinical trial registered with www.clinicaltrials.gov (NCT01936831).
Authors: Johan W Mouton; Paul G Ambrose; Rafael Canton; George L Drusano; Stephan Harbarth; Alasdair MacGowan; Ursula Theuretzbacher; John Turnidge Journal: Drug Resist Updat Date: 2011-03-26 Impact factor: 18.500
Authors: Veronique De Jager; Lize van der Merwe; Amour Venter; Peter R Donald; Andreas H Diacon Journal: Antimicrob Agents Chemother Date: 2017-03-24 Impact factor: 5.191
Authors: Robin J Svensson; Elin M Svensson; Rob E Aarnoutse; Andreas H Diacon; Rodney Dawson; Stephen H Gillespie; Mischka Moodley; Martin J Boeree; Ulrika S H Simonsson Journal: J Infect Dis Date: 2018-08-14 Impact factor: 5.226
Authors: Natasha Strydom; Sneha V Gupta; William S Fox; Laura E Via; Hyeeun Bang; Myungsun Lee; Seokyong Eum; TaeSun Shim; Clifton E Barry; Matthew Zimmerman; Véronique Dartois; Radojka M Savic Journal: PLoS Med Date: 2019-04-02 Impact factor: 11.069
Authors: Agathe Béranger; Adrie Bekker; Belén P Solans; Mark F Cotton; Mark Mirochnick; Avy Violari; Jiajia Wang; Mae Cababasay; Lubbe Wiesner; Renee Browning; Jack Moye; Edmund V Capparelli; Radojka M Savic Journal: Clin Infect Dis Date: 2022-09-29 Impact factor: 20.999